脂肪衰减参数联合生化指标对非酒精性脂肪性肝病的诊断价值

肝脏 ›› 2018, Vol. 23 ›› Issue (9): 818-822.

脂肪衰减参数联合生化指标对非酒精性脂肪性肝病的诊断价值

吴琦琦, 孙红霞, 庄小芳, 王晓波, 郭峰, 王燕

830000 新疆新疆医科大学第四附属医院(吴琦琦,庄小芳,王晓波,郭峰,王燕);哈密地区中心医院内分泌科(孙红霞)

收稿日期:2017-11-26 出版日期:2018-09-30 发布日期:2020-04-26
通讯作者: 王燕,Email:wy751105@126.com
基金资助:
新疆科技援疆计划(2016E02067)

Received:2017-11-26 Online:2018-09-30 Published:2020-04-26

摘要/Abstract

摘要： 目的探讨脂肪衰减参数联合生化指标对非酒精性脂肪性肝病(NAFLD)的诊断价值。方法纳入2016年3月至2017年6月就诊于新疆医科大学附属中医医院的145例NAFLD患者,35名健康体检者作为对照,以CT肝/脾比值为诊断标准绘制ROC曲线,计算曲线下面积,评价脂肪衰减参数对NAFLD的诊断价值。结果脂肪衰减参数诊断脂肪肝的最佳cut-off值是262.5 dB/m(AUROC= 0.854,灵敏度=0.840,特异度=0.771);脂肪衰减参数诊断脂肪肝轻度、中度、重度的最佳cut-off值分别是225.5 dB/m、267.5 dB/m、289.5 dB/m,AUROC分别为0.401、0.644、0.807,均P<0.05;脂肪衰减参数联合ALT或TG可提高对NAFLD诊断价值,其中脂肪衰减参数联合ALT的诊断效能更高。结论脂肪衰减参数联合ALT、TG对NAFLD具有更高的诊断效能。

吴琦琦, 孙红霞, 庄小芳, 王晓波, 郭峰, 王燕. 脂肪衰减参数联合生化指标对非酒精性脂肪性肝病的诊断价值[J]. 肝脏, 2018, 23(9): 818-822.

参考文献

[1] Temple JL,Cordero P,Li J,et al. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci,2016,17:E947.
[2] 徐燕华,欧强.非酒精性脂肪性肝炎相关肝细胞癌研究进展.肝脏,2016,21:1074-1076.
[3] Ballestri S,Lonardo A,Bonapace S,et al.Risk of cardiovascular,cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.World J Gastroenterol,2014,20:1724-1745.
[4] Deng H,Wang CL,Lai J,et al.Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients.Hepat Mon,2016,16:e40263.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版).中华肝脏病杂志,2010,18:163-166.
[6] Benedict M,Zhang X.Non-alcoholic fatty liver disease: An expanded review.World J Hepatol,2017,9:715-732.
[7] Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease: the major impact of China.Hepatology, 2014,60:2099-2108.
[8] Cheah MC,McCullough AJ,Goh GB.Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease.J Clin Transl Hepatol,2017,5:261-271.
[9] Wang CY,Lu W,Hu DS,et al.Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. World J Gastroenterol,2014,20:10585-10590.
[10] Shen F,Zheng RD,Mi YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol,2014,20:4702-4711.
[11] 杨硕,吕栋,王天懿,等.FibroTouch^○R脂肪衰减参数对非酒精性脂肪性肝病患者肝脏脂肪变程度的诊断价值.实用肝脏病杂志,2016,19:50-54.
[12] Lückhoff HK,Kruger FC,Kotze MJ.Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol,2015,7:1192-1208.